Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xilio Therapeutics (XLO) Other Non-Current Liabilities (2025)

Xilio Therapeutics (XLO) has disclosed Other Non-Current Liabilities for 1 consecutive years, with $29.6 million as the latest value for Q4 2025.

  • Quarterly Other Non-Current Liabilities changed N/A to $29.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $29.6 million through Dec 2025, changed N/A year-over-year, with the annual reading at $29.6 million for FY2025, N/A changed from the prior year.
  • Other Non-Current Liabilities hit $29.6 million in Q4 2025 for Xilio Therapeutics, down from $53.9 million in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $53.9 million in Q3 2025 to a low of $29.6 million in Q4 2025.